Can Allergan go higher?

In April 2014, Bill Ackman shocked the world of activist investing yet again with an audacious bid to press botox-manufacturer Allergan to sell itself to Canada’s Valeant Pharmaceuticals International. In this campaign review, I analyst the bullish analyst perspective, and explain that Ackman is really bidding for Valeant.

Screen shot 2014-07-07 at 21.35.49


From the May 2014 edition of Activism Monthly Premium, published by Activist Insight.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: